Immunophenotype of UG3 Cells Maintained in IL-3, GM-CSF, M-CSF, and G-CSF
| . | IL-3 . | GM-CSF . | M-CSF . | G-CSF . |
|---|---|---|---|---|
| CD11b | 99.7% | 99.9% | 99.9% | 99.0% |
| CD11c | 96.7% | 99.2% | 99.7% | 99.0% |
| CD13 | 41.2% | 52.9% | 48.1% | 77.1% |
| CD14 | 3.1% | 5.2% | 23.5% (98.6%) | 53.3% |
| CD16 | 0.2% | 0.3% | 0.2% | |
| CD33 | 99.7% | 99.0% | 99.6% | 98.7% |
| CD36 | 48.4% | 44.7% | 47.3 | |
| CD54 | 87.3% | 88.9% | 81.4% | 69.5% |
| CD64 | 99.5% | 99.0% | 99.6% | 98.6% |
| CD68 | 3.2% | 65.8% | 85.2% | |
| CD71 | 94.3% | 87.7% | 45.3% (0.1%) | |
| HLA-DR | 96.0% | 96.6% | 62.9% | 46.3% |
| G-CSF R | 73.9% | 60.9% | 52.3% | 60.7% |
| . | IL-3 . | GM-CSF . | M-CSF . | G-CSF . |
|---|---|---|---|---|
| CD11b | 99.7% | 99.9% | 99.9% | 99.0% |
| CD11c | 96.7% | 99.2% | 99.7% | 99.0% |
| CD13 | 41.2% | 52.9% | 48.1% | 77.1% |
| CD14 | 3.1% | 5.2% | 23.5% (98.6%) | 53.3% |
| CD16 | 0.2% | 0.3% | 0.2% | |
| CD33 | 99.7% | 99.0% | 99.6% | 98.7% |
| CD36 | 48.4% | 44.7% | 47.3 | |
| CD54 | 87.3% | 88.9% | 81.4% | 69.5% |
| CD64 | 99.5% | 99.0% | 99.6% | 98.6% |
| CD68 | 3.2% | 65.8% | 85.2% | |
| CD71 | 94.3% | 87.7% | 45.3% (0.1%) | |
| HLA-DR | 96.0% | 96.6% | 62.9% | 46.3% |
| G-CSF R | 73.9% | 60.9% | 52.3% | 60.7% |
UG3 cells were cultured in IMDM supplemented with 5% FCS and IL-3 (5 ng/mL), GM-CSF (1 ng/mL), M-CSF (100 ng/mL), or G-CSF (10 ng/mL), respectively, for 2 weeks. The immunophenotype was then analyzed by flow cytometry, except for CD68, which was analyzed by immunohistochemistry. The numbers are the percentage of positive cells overall. The numbers in parentheses are the percentage of positive nonadherent large cells in the cells cultured in the presence of M-CSF.